In a phase II trial, imatinib – a first-in-class tyrosine kinase inhibitor (TKI) that has had remarkable success for the treatment of chronic myelogenous leukaemia – preserved β-cell function in individuals with recent-onset type 1 diabetes (T1D), underpinning its potential to alter the course of T1D.
The presence of certain autoantibodies during the first trimester in women with gestational diabetes may point to an increased risk of type 1 diabetes (T1DM) in the long run, according to long-term follow-up of a prospective study from Finland presented at the European Society of Endocrinology virtual conference (e-ECE 2021).
Middle-aged and older adults with overweight or obesity should aim to reduce at least 7.5 percent of their weight, as opposed to keeping it stable, to reduce the risk of having their knee replaced, according to a study. Furthermore, weight gain is detrimental, as it puts them at risk of hip replacement.
New drug applications approved by US FDA as of 16-31 July 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The dual SGLT1/2* inhibitor sotagliflozin significantly lowers the risk of the composite outcome of cardiovascular (CV) deaths, hospitalizations for heart failure (HHF), and urgent visits for heart failure in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), regardless of albuminuria status, according to the SCORED trial presented at ADA 2021.
In patients with type 2 diabetes (T2D), once-weekly doses of the dual glucose-dependent insulinotropic polypeptide–GLP-1* receptor agonist tirzepatide for 40 weeks resulted in superior HbA1c reductions compared with the GLP-1 receptor agonist semaglutide, according to results from the phase III SURPASS-2** trial presented at ADA 2021.
A three-component lifestyle intervention (LSI) programme* was effective in improving the metabolic health and weight of reproductive-aged women with polycystic ovarian syndrome (PCOS), according to data presented at ESHRE 2021.
In patients with type 2 diabetes (T2D) with cardiovascular (CV) risk factors or impaired kidney function, weekly doses of the exendin-based GLP-1* receptor agonist (RA) efpeglenatide may reduce their risk of major adverse cardiovascular events (MACE) or kidney outcomes, according to findings from the AMPLITUDE-O trial presented at ADA 2021.
A study of Chinese adults has found a protective benefit with daily green tea consumption against incident type 2 diabetes (T2D), as well as all-cause mortality in patients with T2D. However, the associations for other types of tea are unclear.